Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris

Main Article Content

David M Pariser
Lawrence J Green
Edward L Lain
Carsten Schmitz
Amy S Chinigo
Brian McNames
David R Berk
Jamison Hoffman
Ayman Grada

Keywords

Acne Vulgaris, Acne, Sarecycline, Safety

Abstract

Abstract not available.

References

Pariser , David M., Lawrence J. Green, Carsten Schmitz, Amy Chinigo , Brian McNamee, and David R. Berk . “Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open Label Study and a Phase I Phototoxicity Study : JCAD: The Journal of Clinical and Aesthetic Dermatology.” JCAD, November 1, 2019. http://jcadonline.com/sarecycline acne //. ClinicalTrials.gov Registration: NCT02413346


Moore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, Cook Bolden FE, Dhawan SS, Forsha D, Gold MH, Guenthner S. Once Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double Blind Clinical Trials. Journal of drugs in dermatology: JDD. 2018 Sep;17(9):987 96 .